PEDF: a potential molecular therapeutic target with multiple anti-cancer activities

Trends in Molecular Medicine

Volumn 12, Issue 10, 2006, Pages 497-502

  Ek, Eugene T H ^a   Dass, Crispin R ^a   Choong, Peter F M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; LIPOSOME; MICROSPHERE; PIGMENT EPITHELIUM DERIVED FACTOR; POLYGLACTIN; PROTEIN; SERPINF1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 17P; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROPROTECTION; NONHUMAN; PROTEIN FAMILY; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

ANGIOGENESIS INHIBITORS; CELL PROLIFERATION; EYE PROTEINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; SERPINS;

EID: 33749158265     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.08.009     Document Type: Review

References (55)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Sebolt-Leopold J.S., and English J.M. Mechanisms of drug inhibition of signalling molecules. Nature 441 (2006) 457-462
3. Jimeno A., and Hidalgo M. Multitargeted therapy: can promiscuity be praised in an era of political correctness?. Crit. Rev. Oncol. Hematol. 59 (2006) 150-158
4. Eastman A., and Perez R.P. New targets and challenges in the molecular therapeutics of cancer. Br. J. Clin. Pharmacol. 62 (2006) 5-14
5. Klein S., et al. Killing time for cancer cells. Nat. Rev. Cancer 5 (2005) 573-580
6. Tombran-Tink J., and Johnson L.V. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest. Ophthalmol. Vis. Sci. 30 (1989) 1700-1707
7. Tombran-Tink J., et al. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res. 53 (1991) 411-414
8. Dawson D.W., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
9. Zhang S.X., et al. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 20 (2006) 323-325
10. Yamagishi S., et al. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res. 320 (2005) 437-445
11. Funatsu H., et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113 (2006) 294-301
12. Hase R., et al. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin. Cancer Res. 11 (2005) 8737-8744
13. Filleur S., et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res. 65 (2005) 5144-5152
14. Doll J.A., et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat. Med. 9 (2003) 774-780
15. Ramirez-Castillejo C., et al. Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat. Neurosci. 9 (2006) 331-339
16. Tsao Y.P., et al. Pigment epithelium-derived factor inhibits oxidative stress-induced cell death by activation of extracellular signal-regulated kinases in cultured retinal pigment epithelial cells. Life Sci. 79 (2006) 545-550
17. Takanohashi, A. et al. (2006) Pigment epithelium-derived factor induces the production of chemokines by rat microglia. Glia [Epub ahead of print]
18. Ek E.T., and Choong P.F. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev. Anticancer Ther. 6 (2006) 225-237
19. Steele F.R., et al. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 1526-1530
20. Tombran-Tink J., et al. Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Mol. Vis. 2 (1996) 4-11
21. Bilak M.M., et al. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J. Neuropathol. Exp. Neurol. 58 (1999) 719-728
22. Kuncl R.W., et al. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J. Neurochem. 81 (2002) 178-184
23. Sawant S., et al. Regulation of factors controlling angiogenesis in liver development: a role for PEDF in the formation and maintenance of normal vasculature. Biochem. Biophys. Res. Commun. 325 (2004) 408-413
24. Uehara H., et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. 64 (2004) 3533-3537
25. Quan G.M., et al. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif. Tissue Int. 76 (2005) 146-153
26. Alberdi E., et al. Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site. Biochemistry 37 (1998) 10643-10652
27. Bilak M.M., et al. Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J. Neurosci. 22 (2002) 9378-9386
28. Meyer C., et al. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J. Biol. Chem. 277 (2002) 45400-45407
29. Alberdi E., et al. Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor. J. Biol. Chem. 274 (1999) 31605-31612
30. Aymerich M.S. Evidence for pigment epithelium-derived factor receptors in the neural retina. Invest. Ophthalmol. Vis. Sci. 42 (2001) 3287-3293
31. Volpert O.V., et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 8 (2002) 349-357
32. Patricia Becerra S. Focus on molecules: pigment epithelium-derived factor (PEDF). Exp. Eye Res. 82 (2006) 739-740
33. Yasui N., et al. Dual-site recognition of different extracellular matrix components by anti-angiogenic/neurotrophic serpin, PEDF. Biochemistry 42 (2003) 3160-3167
34. Hosomichi J., et al. Involvement of the collagen I-binding motif in the anti-angiogenic activity of pigment epithelium-derived factor. Biochem. Biophys. Res. Commun. 335 (2005) 756-761
35. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
36. Tombran-Tink J., and Barns C.J. PEDF: a multifaceted neurotrophic factor. Nat. Rev. Neurosci. 4 (2003) 628-636
37. Halin S., et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res. 64 (2004) 5664-5671
38. Uehara H., et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. 64 (2004) 3533-3537
39. Guan M., et al. Loss of pigment epithelium derived factor expression in glioma progression. J. Clin. Pathol. 56 (2003) 277-282
40. Sidle D.M., et al. Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence. Arch. Otolaryngol. Head Neck Surg. 131 (2005) 990-995
41. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol. Med. 8 (2002) 330-334
42. Cai J., et al. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of VEGFR-1. J. Biol. Chem. 281 (2006) 3604-3613
43. Ogata N., et al. Upregulation of pigment epithelium-derived factor after laser photocoagulation. Am. J. Ophthalmol. 132 (2001) 427-429
44. Holekamp N.M., et al. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. 134 (2002) 220-227
45. Quan, G.M. et al. (2002-2003) Resistance of epiphyseal cartilage to invasion by osteosarcoma is likely to be due to expression of antiangiogenic factors. Pathobiology 70, 361-367
46. Takenaka K., et al. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci. 77 (2005) 3231-3241
47. Zhang L., et al. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int. J. Mol. Med. 17 (2006) 937-944
48. Abe R., et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am. J. Pathol. 164 (2004) 1225-1232
49. Garcia M., et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res. 64 (2004) 5632-5642
50. Streck C.J., et al. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J. Pediatr. Surg. 40 (2005) 236-243
51. Abramson L.P., et al. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J. Pediatr. Surg. 38 (2003) 336-342
52. Crawford S.E., et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J. Cell Sci. 114 (2001) 4421-4428
53. Zhang L., et al. Down-regulation of PEDF expression by ribozyme transgene in endothelial and lung cancer cells and its impact on angiogenesis in vitro. Oncol. Rep. 14 (2005) 1615-1619
54. Quan G.M., et al. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif. Tissue Int. 76 (2005) 146-153
55. Li H., et al. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp. Eye Res. 83 (2006) 824-833